- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01696175
PICU Admission Lactate and Central Venous Oxymetry Study (PALVOS)
Lactate Levels and Venous Oxygen Saturation in Children Admitted to a Dutch PICU
Study Overview
Status
Conditions
Detailed Description
Rationale: Hemodynamic therapy in children with circulatory insufficiency requires the use of hemodynamic monitoring parameters including parameters that reflect tissue/organ oxygenation and oxygen utilization. Two parameters are readily available at the bedside that may reflect this: arterial lactate level and central venous oxygen saturation (ScvO2). To date is it unknown if these parameters are useful in guiding treatment of critically ill children. Also it is unknown how often lactate and ScvO2 are abnormal in children admitted to a Dutch PICU or if they are related to each.
Objective: The objective of this study is to find the incidence of a raised lactate level and or a decreased ScvO2, to study their mutual relation and to study the relation between lactate, ScvO2 and outcome parameters in children admitted to a Dutch PICU.
Study design: Observational cohort study
Study population: children admitted to a PICU <= 16 years
Intervention (if applicable): No intervention
Main study parameters/endpoints: Arterial lactate level, central venous oxygen saturation (ScvO2), arterial blood gas analysis and general hemodynamic variables in the first 24 hours after admission. Parameters for organ dysfunction, severity of illness and outcome parameters like length of PICU stay.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: This is a strict observational design. No blood samples are taken for the purpose of this study. No intravascular catheters are inserted for the purpose of this study. No treatment strategy is associated with this study.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Nijmegen, Netherlands
- RUNMC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Al children admitted to a PICU <= 16 years equipped with an arterial and central venous catheter in situ at admission or inserted within < 12 hours after admission to the PICU
Exclusion Criteria:
- Patients without an arterial or central venous catheter > 12 hours after of admission
- Patients with a known underlying metabolic disorder causing an elevated lactate level
- Patients with asthma and therapy (nebulized or intravenous) with salbutamol.
- Patients with an intoxication causing elevated lactate levels
- Premature children (<38 weeks GA)
- Patients on ECMO
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
PICU admittance
Children equipped with an arterial and a central venous catheter within 12 hours after admittance to a Dutch PICU
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
What is the incidence of a decreased ScvO2 and or a raised lactate level in children admitted to Dutch PICU's in the first 24 hours after admission to the PICU
Time Frame: first 24 hours after admission
|
What is the incidence of a decreased ScvO2 and or a raised lactate level in children admitted to Dutch PICU's in the first 24 hours after admission to the PICU
|
first 24 hours after admission
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PALVOS
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Shock
-
Assistance Publique - Hôpitaux de ParisTraumabase Group; Capgemini Invent; Ecole polytechnique; EHESS (Ecole des hautes... and other collaboratorsRecruitingWounds and Injuries | Hemorrhagic Shock | Traumatic ShockFrance
-
Biomedizinische Forschungs gmbHMedical University of ViennaCompletedSepsis | Toxic-Shock Syndrome
-
King's College Hospital NHS TrustUniversity Hospital BirminghamCompletedTraumatic Haemorrhagic ShockUnited Kingdom
-
Haukeland University HospitalMinistry of Defence, NorwayCompletedHemorrhagic Shock | Hypovolemic ShockNorway
-
Massachusetts General HospitalBeth Israel Deaconess Medical Center; Boston Medical Center; Tufts Medical Center and other collaboratorsRecruiting
-
Jason SperryNational Heart, Lung, and Blood Institute (NHLBI)TerminatedHemorrhagic ShockUnited States
-
University of Texas Southwestern Medical CenterUniversity of Washington; Resuscitation Outcomes ConsortiumCompletedHemorrhagic ShockUnited States
-
Ramathibodi HospitalUnknownSeptic Shock | Refractory ShockThailand
-
National Institute of Allergy and Infectious Diseases...Completed
-
Assiut UniversityUnknown